Rees E, Kirov G, Sanders A, et al. Evidence that duplications of 22q11.2 protect against schizophrenia. Mol Psychiatry. 2014;19(1):37-40. doi:10.1038/mp.2013.156
Duncan LE, Holmans PA, Lee PH, et al. Pathway analyses implicate glial cells in schizophrenia. PLoS One. 2014;9(2):e89441. doi:10.1371/journal.pone.0089441
Bergen SE, O’Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. Schizophr Res. 2014;154(1-3):48-53. doi:10.1016/j.schres.2014.01.030
Hyman SE. Time for new schizophrenia Rx. Science. 2014;343(6176):1177. doi:10.1126/science.1252603
Hyman SE. Perspective: Revealing molecular secrets. Nature. 2014;508(7494):S20. doi:10.1038/508S20a
Szatkiewicz JP, O’Dushlaine C, Chen G, et al. Copy number variation in schizophrenia in Sweden. Mol Psychiatry. 2014;19(7):762-73. doi:10.1038/mp.2014.40
Juraeva D, Haenisch B, Zapatka M, et al. Integrated pathway-based approach identifies association between genomic regions at CTCF and CACNB2 and schizophrenia. PLoS Genet. 2014;10(6):e1004345. doi:10.1371/journal.pgen.1004345
Georgieva L, Rees E, Moran JL, et al. De novo CNVs in bipolar affective disorder and schizophrenia. Hum Mol Genet. 2014;23(24):6677-83. doi:10.1093/hmg/ddu379
Robinson EB, Samocha KE, Kosmicki JA, et al. Autism spectrum disorder severity reflects the average contribution of de novo and familial influences. Proc Natl Acad Sci U S A. 2014;111(42):15161-5. doi:10.1073/pnas.1409204111
Jackson J, Eaton W, Cascella N, et al. Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia. Schizophr Res. 2014;159(2-3):539-42. doi:10.1016/j.schres.2014.09.023